Alexandra L. Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alexandra L. Lee has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Thomas F. Bateson
U.S. Environmental Protection Agency, Washington, DC, USA
3 shared publications - Elizabeth G. Radke
Center for Public Health and Environmental Assessment, U.S. Environmental Protection Agency, Washington, District of Columbia, USA
2 shared publications - Hongyu Ru
U.S. Environmental Protection Agency, Office of Research and Development, Center for Public Health and Environmental Assessment, Chemical and Pollutant Assessment Division
2 shared publications - Kristen M. Rappazzo
U.S. EPA, Center For Public Health and Environmental Assessment, Research Triangle Park, NC 27711, United States
2 shared publications - Michael W. Dzierlenga
Center for Public Health and Environmental Assessment, Office of Research and Development, US Environmental Protection Agency, Washington DC, USA
2 shared publications - Rachel M. Shaffer
Center for Public Health and Environmental Assessment, Office of Research and Development, US EPA, DC, Washington, USA
2 shared publications
Latest Publications
- Open Access
- 15 March 2026
- Published by Elsevier in SSRN Electronic Journal
Systematic Review and Meta-analysis of Birth Weight and Prenatal Exposure to Perfluoroundecanoic Acid
BackgroundDue to transplacental exposure to perfluoroundecanoic acid (PFUnDA), there is a need to evaluate potential developmental effects in humans. We examined the association between PFUnDA exposure and birth weight (BW) using systematic review methodology.MethodsWe used a random effects model with inverse-variance weighting to meta-analyze associations between PFUnDA exposure biomarkers and changes in BW. We report a pooled estimate and stratified estimates based on factors including study confidence and timing of sample collection.ResultsWe detected a pooled mean BW deficit (β) of 15.3 g (95%CI: -23.4, -7.1) per ln(ng/mL) PFUnDA increase in our primary analysis of 28 studies. We observed deficits in 5 low (β= -26.3 g, 95%CI: -56.5, 3.8), 14 medium (β= -16.5 g, 95%CI: -26.8, -6.1), and 9 high confidence studies (β = -10.3 g, 95%CI: -24.8, 4.1). The magnitude of the pooled BW deficit varied across sample timing categories, with the largest average deficit in eight studies with postpartum samples (β = -21.0 g, 95%CI: -43.8, 1.8) and the smallest among eight studies with early pregnancy samples (β = -6.8 g, 95%CI: -21.5, 7.9).ConclusionsWe observed lower BW associated with higher PFUnDA exposure. Although confidence intervals overlapped across strata, we detected smaller BW deficits in higher quality studies and larger deficits among studies that collected samples in late pregnancy or postpartum. These trends may be partly explained by bias from pregnancy hemodynamics. Future studies conducted in populations with serial pregnancy PFUnDA measures would facilitate data interpretation and address some methodological challenges.
- 15 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSystematic Review and Meta-analysis of Birth Weight and Prenatal Exposure to Perfluoroundecanoic Acid
BackgroundDue to transplacental exposure to perfluoroundecanoic acid (PFUnDA), there is a need to evaluate potential developmental effects in humans. We examined the association between PFUnDA exposure and birth weight (BW) using systematic review methodology.MethodsWe used a random effects model with inverse-variance weighting to meta-analyze associations between PFUnDA exposure biomarkers and changes in BW. We report a pooled estimate and stratified estimates based on factors including study confidence and timing of sample collection.ResultsWe detected a pooled mean BW deficit (β) of 15.3 g (95%CI: -23.4, -7.1) per ln(ng/mL) PFUnDA increase in our primary analysis of 28 studies. We observed deficits in 5 low (β= -26.3 g, 95%CI: -56.5, 3.8), 14 medium (β= -16.5 g, 95%CI: -26.8, -6.1), and 9 high confidence studies (β = -10.3 g, 95%CI: -24.8, 4.1). The magnitude of the pooled BW deficit varied across sample timing categories, with the largest average deficit in eight studies with postpartum samples (β = -21.0 g, 95%CI: -43.8, 1.8) and the smallest among eight studies with early pregnancy samples (β = -6.8 g, 95%CI: -21.5, 7.9).ConclusionsWe observed lower BW associated with higher PFUnDA exposure. Although confidence intervals overlapped across strata, we detected smaller BW deficits in higher quality studies and larger deficits among studies that collected samples in late pregnancy or postpartum. These trends may be partly explained by bias from pregnancy hemodynamics. Future studies conducted in populations with serial pregnancy PFUnDA measures would facilitate data interpretation and address some methodological challenges.
- Open Access
- 17 September 2025
- Published by Elsevier in Environment International
- Vol. 205, 109786
Lead exposure and antisocial behavior: A systematic review of human and animal evidence
- 17 September 2025
- Published by Elsevier in Environment International
- Vol. 205, 109786
Open AccessLead exposure and antisocial behavior: A systematic review of human and animal evidence
- 1 April 2025
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 133 (3-4)
A Perspective from US Environmental Protection Agency (EPA) Scientists: How Your Epidemiologic Analyses Can Inform the Human Health Risk Assessment Process
Environmental epidemiologists strive to conduct research that will lead to actions that improve public health outcomes. The risk assessment process is the bridge between scientific research and policies that can impact public health. Historically, epidemiologic studies have not frequently been used to inform U.S. Environmental Protection Agency (EPA) assessments outside of the context of air pollution. There are certain practices that can be adopted by the epidemiology community to facilitate the integration of epidemiologic studies into policy-relevant assessments. The central objective of this commentary is to provide guidance to epidemiologists that will enhance the value of their studies for EPA assessments. First, we provide an overview of EPA dose-response and toxicity value derivation to increase literacy about these processes across the environmental epidemiology community. Second, we provide suggestions for modeling and reporting to facilitate the use of epidemiologic studies in EPA dose-response assessments that form the basis for decision-making. Epidemiologic research can be utilized in all aspects of dose-response assessment, which involves identifying a point of departure followed by specific adjustments and/or extrapolations to identify a toxicity value intended to prevent adverse effects across the population. To facilitate integration of epidemiologic research into the dose-response assessment process, we provide specific recommendations for additional modeling (e.g., modeling in the low exposure range; exploring non-linearity) and reporting (e.g., sufficient information to conduct study evaluation; details on exposure levels in the population) in published epidemiologic research. Many of these suggestions require only additional reporting in the final manuscript or associated appendices but would have substantial impact on the contribution of the published work to the assessment process. https://doi.org/10.1289/EHP15203.
- 1 April 2025
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 133 (3-4)
A Perspective from US Environmental Protection Agency (EPA) Scientists: How Your Epidemiologic Analyses Can Inform the Human Health Risk Assessment Process
Environmental epidemiologists strive to conduct research that will lead to actions that improve public health outcomes. The risk assessment process is the bridge between scientific research and policies that can impact public health. Historically, epidemiologic studies have not frequently been used to inform U.S. Environmental Protection Agency (EPA) assessments outside of the context of air pollution. There are certain practices that can be adopted by the epidemiology community to facilitate the integration of epidemiologic studies into policy-relevant assessments. The central objective of this commentary is to provide guidance to epidemiologists that will enhance the value of their studies for EPA assessments. First, we provide an overview of EPA dose-response and toxicity value derivation to increase literacy about these processes across the environmental epidemiology community. Second, we provide suggestions for modeling and reporting to facilitate the use of epidemiologic studies in EPA dose-response assessments that form the basis for decision-making. Epidemiologic research can be utilized in all aspects of dose-response assessment, which involves identifying a point of departure followed by specific adjustments and/or extrapolations to identify a toxicity value intended to prevent adverse effects across the population. To facilitate integration of epidemiologic research into the dose-response assessment process, we provide specific recommendations for additional modeling (e.g., modeling in the low exposure range; exploring non-linearity) and reporting (e.g., sufficient information to conduct study evaluation; details on exposure levels in the population) in published epidemiologic research. Many of these suggestions require only additional reporting in the final manuscript or associated appendices but would have substantial impact on the contribution of the published work to the assessment process. https://doi.org/10.1289/EHP15203.
- 9 May 2024
- Published by BMJ in Occupational and Environmental Medicine
- Vol. 81 (5) , 266-276
Systematic review and meta-analysis of birth weight and perfluorohexane sulfonate exposures: examination of sample timing and study confidence
We examined the association between mean birth weight (BW) differences and perfluorohexane sulfonate (PFHxS) exposure biomarkers.We fit a random effects model to estimate the overall pooled effect and for different strata based on biomarker sample timing and overall study confidence. We also conducted an analysis to examine the impact of a continuous measure of gestational age sample timing on the overall pooled effect.We detected a −7.9 g (95% CI −15.0 to –0.7; pQ=0.85; I2=0%) BW decrease per ln ng/mL PFHxS increase based on 27 studies. The 11 medium confidence studies (β=−10.0 g; 95% CI −21.1 to 1.1) showed larger deficits than 12 high (β=−6.8 g; 95% CI −16.3 to 2.8) and 4 low confidence studies (β=−1.5 g; 95% CI −51.6 to 48.7). 10 studies with mid-pregnancy to late-pregnancy sampling periods showed smaller deficits (β=−3.9 g; 95% CI −17.7 to 9.9) than 5 post-partum studies (β=−28.3 g; 95% CI −69.3 to 12.7) and 12 early sampling studies (β=−7.6 g; 95% CI −16.2 to 1.1). 6 of 12 studies with the earliest sampling timing showed results closer to the null.Overall, we detected a small but statistically significant BW deficit across 27 studies. We saw comparable BW deficit magnitudes in both the medium and high confidence studies as well as the early pregnancy group. Despite no definitive pattern by sample timing, larger deficits were seen in postpartum studies. We also saw results closer to the null for a subset of studies restricted to the earliest biomarker collection times. Serial pregnancy sampling, improved precision in gestational age estimates and more standardised reporting of sample variation and exposure units in future epidemiologic research may offer a greater understanding of the relationship between PFHxS on BW and any potential impact of pregnancy haemodynamics.
- 9 May 2024
- Published by BMJ in Occupational and Environmental Medicine
- Vol. 81 (5) , 266-276
Systematic review and meta-analysis of birth weight and perfluorohexane sulfonate exposures: examination of sample timing and study confidence
We examined the association between mean birth weight (BW) differences and perfluorohexane sulfonate (PFHxS) exposure biomarkers.We fit a random effects model to estimate the overall pooled effect and for different strata based on biomarker sample timing and overall study confidence. We also conducted an analysis to examine the impact of a continuous measure of gestational age sample timing on the overall pooled effect.We detected a −7.9 g (95% CI −15.0 to –0.7; pQ=0.85; I2=0%) BW decrease per ln ng/mL PFHxS increase based on 27 studies. The 11 medium confidence studies (β=−10.0 g; 95% CI −21.1 to 1.1) showed larger deficits than 12 high (β=−6.8 g; 95% CI −16.3 to 2.8) and 4 low confidence studies (β=−1.5 g; 95% CI −51.6 to 48.7). 10 studies with mid-pregnancy to late-pregnancy sampling periods showed smaller deficits (β=−3.9 g; 95% CI −17.7 to 9.9) than 5 post-partum studies (β=−28.3 g; 95% CI −69.3 to 12.7) and 12 early sampling studies (β=−7.6 g; 95% CI −16.2 to 1.1). 6 of 12 studies with the earliest sampling timing showed results closer to the null.Overall, we detected a small but statistically significant BW deficit across 27 studies. We saw comparable BW deficit magnitudes in both the medium and high confidence studies as well as the early pregnancy group. Despite no definitive pattern by sample timing, larger deficits were seen in postpartum studies. We also saw results closer to the null for a subset of studies restricted to the earliest biomarker collection times. Serial pregnancy sampling, improved precision in gestational age estimates and more standardised reporting of sample variation and exposure units in future epidemiologic research may offer a greater understanding of the relationship between PFHxS on BW and any potential impact of pregnancy haemodynamics.